|
Morgan Stanley initiated coverage on Swiggy with an 'Overweight' rating and a price target of Rs 405, indicating a 22% upside. The brokerage highlighted strong growth potential in food delivery and quick commerce, valuing Swiggy as an emerging competitor to market leader Zomato with significant long-term earnings prospects.
Category:
News and Media
Sun Pharma Advanced Research Company (SPARC) psoriasis drug, Vibozilimod (SCD-044), failed to meet primary endpoints in Phase 2 trials for psoriasis and atopic dermatitis. The company has decided to discontinue development of the drug. Separately, a surprise FDA inspection is underway at Sun Pharmas Halol manufacturing facility.
Category:
News and Media
The charity is moving to a new site so it can help more families in need with essential supplies.
Category:
News and Media
All news |
||||||||||||||||||
|